Skip to main content

Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD) and Veeva Systems (VEEV)

Tipranks - Tipranks - Fri Mar 6, 2:14AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mediwound (MDWD – Research Report) and Veeva Systems (VEEV – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Mediwound (MDWD)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Mediwound yesterday. The company’s shares closed last Wednesday at $17.60.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 32.1% and a 57.4% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Diamedica Therapeutics, and Fennec Pharmaceuticals. ;'>

Mediwound has an analyst consensus of Strong Buy, with a price target consensus of $29.00.

See the top stocks recommended by analysts >>

Veeva Systems (VEEV)

Barclays analyst Saket Kalia maintained a Buy rating on Veeva Systems today and set a price target of $250.00. The company’s shares closed last Wednesday at $188.48.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 4.0% and a 50.6% success rate. Kalia covers the Technology sector, focusing on stocks such as CCC Intelligent Solutions Holdings, Procore Technologies, and Rubrik, Inc. Class A. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veeva Systems with a $256.10 average price target, representing a 37.3% upside. In a report issued on February 19, TipRanks – xAI also upgraded the stock to Buy with a $200.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).